Clinical Trials

With a history of billion-dollar deals, Mark Altmeyer takes the helm at ReproNovo, aiming to commercialize its promising fertility and women's health pipeline.

An influential guidelines update expands options for a tough-to-treat bladder cancer, giving patients access to a novel gene therapy beyond its FDA label.

Belief BioMed's single-dose treatment for hemophilia B, BBM-H901, is now approved in Macao, offering a new horizon for patients beyond frequent injections.

With fresh funding secured, Dogwood Therapeutics pushes its promising nerve pain drug, Halneuron®, toward a pivotal data readout later this year.

InflaRx announces a late-breaking presentation on its Phase 3 trial for vilobelimab, offering potential new hope for pyoderma gangrenosum patients.

SAB Biotherapeutics' public offering fuels late-stage trials for its promising T1D drug, SAB-142, aiming to change the treatment landscape.

The FDA grants PolyPid a crucial $4.3 million fee waiver for its D-PLEX₁₀₀ drug, freeing up vital cash to accelerate its commercial launch.

Galectin Therapeutics adds legendary neurosurgeon Dr. Henry Brem to its board, a strategic move to leverage his drug development expertise for its lead liver drug.

As maternity care deserts expand, one rural hospital is using wearable tech to bring vital prenatal monitoring to high-risk mothers right in their homes.

A partnership between Biophytis and LynxKite leverages AI to fast-track therapies for sarcopenia and macular degeneration, backed by Singapore's RIE 2030 plan.

Theriva Biologics pushes its promising cancer virus toward pivotal trials, but an auditor's 'going concern' warning raises questions about its future.

Biotech leader H. Martin Seidel joins Odyssey's SAB, a strategic move signaling accelerated development in the competitive autoimmune disease space.

With its novel glaucoma drug QLS-111 entering Phase 3, Qlaris Bio brings in seasoned leader Fred Guerard to navigate the final trials and path to market.

Eledon's tegoprubart gets Orphan Drug status, signaling a new era for liver transplant patients by potentially replacing toxic, decades-old therapies.

Relmada Therapeutics stock skyrockets on promising bladder cancer data and a $160M financing deal, setting a high-stakes stage for its investor conference.

IDEAYA Biosciences begins a key trial for its targeted therapy IDE892, aiming to conquer hard-to-treat tumors and pivoting to focus on its proprietary assets.

Biotech firm Immunis, Inc. secures a promising drug candidate to treat a debilitating side effect of Parkinson's therapy, offering hope to millions.

With strong revenue growth and critical FDA decisions on the horizon, MannKind's leadership prepares to outline its vision for investors in Miami.

Immunome announces stellar Phase 3 data for its desmoid tumor drug, varegacestat, and details a robust, well-funded ADC pipeline aimed at solid tumors.

The D.C. transplant institute surpasses a historic milestone, pioneering new tech and giving thousands a second chance at life amid a national organ shortage.